A pilot study subsequently conducted by Holst in collaboration with Mette Zander at Hvidovre Hospital between September 1999 and October 2000 indicated that continuous subcutaneous infusions of synthetic GLP-1 over 6 weeks into patients with quite severe type 2 diabetes dramatically improved their blood sugar control, lowered glycated haemoglobin levels and decreased their body weight
In general, the goal is to keep injections about one week apart to ensure steady effectiveness and minimise side effects
NICE guidance specifies a maximum treatment duration of two years in this setting
Brain slice studies have shown that exendin-4 can increase the firing rates of DMH neurons, enhancing the neurons sensitivity to a high-fat diet (HFD) compared to a control diet [72]
In trials, a structured dose-escalation schedule was used specifically to minimise gastrointestinal tolerability issues
Clinical trials have also reported improvements in glycaemic parameters, including HbA1c, and favourable changes in selected metabolic markers
